Access keys

Skip to content Accessibility Home News, events and publications Site map Search Privacy policy Help Contact us Terms of use

New vaccine design shows promise in protecting against African Horse Sickness Virus

Copyright: iStock
News from: London School of Hygiene & Tropical Medicine

An effective vaccine protecting against all nine strains of African Horse Sickness Virus is a step closer, according to new research published in the journal Vaccine.

The study, led by the London School of Hygiene & Tropical Medicine and funded by the Biotechnology and Biological Sciences Research Council (BBSRC), used a type of vaccine that possesses all the benefits of a traditional vaccine with none of the associated risk factors. It is the first to report a ‘reverse genetics’ based vaccine for African Horse Sickness Virus (AHSV) and highlights its great potential in controlling the disease.

African Horse Sickness is a devastating disease affecting species in the horse family. It causes severe respiratory problems and approximately 90% of horses that catch it die within a week. AHSV is endemic to sub-Saharan Africa although there have also been known outbreaks in Spain and Portugal. The biting midges that transmit the disease are found all across Europe and there is concern regarding the influence of climate change on midge populations.

Many countries use a ‘live’ vaccine to treat AHSV. These vaccines render pathogens harmless, vastly reducing their ability to infect a host, however, the current version for AHSV is considered unsafe. This is due to the possibility of the virus becoming infectious again due to mutations in the vaccine strains, causing African Horse Sickness in the host animal.

In 2016, the school-led research team developed a ‘reverse genetics’ system that enabled strains to mimic viruses, demonstrating their same abilities to enter host cells and initiate an immune response. However, unlike the natural virus the vaccine strains are unable to replicate, rendering them harmless. This ‘Entry Competent Replication-Abortive’ (ECRA) system allowed for the development of virus strains for all nine types of AHSV and a successful mouse model displayed the potential for vaccine development.

In this latest study, researchers tested the effectiveness of a single vaccine strain and a ‘cocktail’ of multiple ECRA-based vaccine strains in eight ponies. As found in the mouse model study, the vaccine viruses were able to enter the cell, triggering strong immune responses but were unable to replicate. None of the eight ponies suffered any adverse effects from the vaccine. When infected, all vaccinated ponies were protected from African Horse Sickness and only the non-vaccinated ponies had clinical symptoms of virus infection.

There has never been an outbreak of AHSV in the UK but higher rates of midge dispersal in European countries, including the UK, increases the risk of a potential outbreak. This could have significant consequences for the UK’s horse industry, which contributes an estimated £7 billion to the UK economy.

Principal study investigator Polly Roy, Professor of Virology at the London School of Hygiene & Tropical Medicine, said: “The high volume of movement in the horse industry increases the risk of the introduction of exotic diseases such as African Horse Sickness. There are well-designed control measures for animal outbreaks in the UK, but measures taken during such an epidemic, such as the restriction of movement, could cost the UK economy approximately £4 billion.

“Using our patented reverse genetics system, the study findings demonstrated that ECRA vaccines triggered strong immune responses in ponies that protected them completely against the virus infection. Our unique and cost-effective vaccine design could act as an example for the development of next generation of vaccines against other vector-borne diseases that undermine the horse industry.”

It is hoped that the development of a safe and effective African Horse Sickness Virus vaccine can afford protection preventing major impact in the event of an outbreak in European countries. As the ECRA-developed vaccine does not require ‘live’ and infectious materials, the vaccine would not only be cost-efficient but it could also be rapidly manufactured. The authors state that further research is needed to determine the optimal dosage requirements and the longevity of the vaccine.


Notes to editors

Publication: Valeria Lulla, Andres Losada, Sylvie Lecollinet, Adeline Kerviel, Thomas Lilin, Corinne Sailleau, Cecile Beck, Stephan Zientara, Polly Roy. Protective efficacy of multivalent replication-abortive vaccine strains in horses against African horse sickness virus challenge. Vaccine. DOI: 10.1016/j.vaccine.2017.06.023.


UK Research and Innovation Media Office

Tags: fundamental bioscience animal health bioscience vaccine development genetics press release